Literature DB >> 12207639

Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity.

Umit Yasar, Marja-Liisa Dahl, Magnus Christensen, Erik Eliasson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12207639      PMCID： PMC1874407          DOI： 10.1046/j.1365-2125.2002.01646.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  8 in total

1.  Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Authors:  Umit Yasar; Cecilia Forslund-Bergengren; Gunnel Tybring; Pedro Dorado; Adrián Llerena; Folke Sjöqvist; Erik Eliasson; Marja-Liisa Dahl
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

Review 2.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

3.  Role of CYP2C9 polymorphism in losartan oxidation.

Authors:  G Tybring; M Hidestrand; M Oscarson; M Ingelman-Sundberg; M L Dahl; E Eliasson
Journal:  Drug Metab Dispos       Date:  2001-07       Impact factor: 3.922

4.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Authors:  R S Kidd; A B Straughn; M C Meyer; J Blaisdell; J A Goldstein; J T Dalton
Journal:  Pharmacogenetics       Date:  1999-02

5.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors:  G P Aithal; C P Day; P J Kesteven; A K Daly
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

6.  Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.

Authors:  R Brandolese; M G Scordo; E Spina; M Gusella; R Padrini
Journal:  Clin Pharmacol Ther       Date:  2001-10       Impact factor: 6.875

7.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

Authors:  U Yasar; E Eliasson; M L Dahl; I Johansson; M Ingelman-Sundberg; F Sjöqvist
Journal:  Biochem Biophys Res Commun       Date:  1999-01-27       Impact factor: 3.575

8.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members.

Authors:  R A Stearns; P K Chakravarty; R Chen; S H Chiu
Journal:  Drug Metab Dispos       Date:  1995-02       Impact factor: 3.922
  8 in total
  8 in total

1.  Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo.

Authors:  Agneta Wennerholm; Anna Nordmark; Maria Pihlsgård; Margarita Mahindi; Leif Bertilsson; Lars L Gustafsson
Journal:  Eur J Clin Pharmacol       Date:  2006-06-17       Impact factor: 2.953

2.  Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9.

Authors:  Anders Helldén; Ulf Bergman; Karin Engström Hellgren; Michèle Masquelier; Ingela Nilsson Remahl; Ingegerd Odar-Cederlöf; Margareta Ramsjö; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2010-04-20       Impact factor: 2.953

3.  The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.

Authors:  Massimiliano Donzelli; Adrian Derungs; Maria-Giovanna Serratore; Christoph Noppen; Lana Nezic; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

4.  Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-28       Impact factor: 2.441

5.  CYP2C9 genetic variants and losartan oxidation in a Turkish population.

Authors:  Melih O Babaoglu; Umit Yasar; Mia Sandberg; Erik Eliasson; Marja-Liisa Dahl; S Oguz Kayaalp; Atila Bozkurt
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

6.  An ethinyl estradiol-levonorgestrel containing oral contraceptive does not alter cytochrome P4502C9 in vivo activity.

Authors:  Ganesh Cherala; Jacob Pearson; Cheryl Maslen; Alison Edelman
Journal:  Drug Metab Dispos       Date:  2013-12-24       Impact factor: 3.922

7.  Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study.

Authors:  Adrian Derungs; Massimiliano Donzelli; Benjamin Berger; Christoph Noppen; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2016-01       Impact factor: 6.447

Review 8.  Influence of CYP2C9 Genetic Polymorphisms on the Pharmacokinetics of Losartan and Its Active Metabolite E-3174: A Systematic Review and Meta-Analysis.

Authors:  Yoon-A Park; Yu-Bin Song; Jeong Yee; Ha-Young Yoon; Hye-Sun Gwak
Journal:  J Pers Med       Date:  2021-06-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.